Replimune stock: Replimune schedules second-quarter results. What it means for Replimune stock

Published on 10/24/2026 at 01:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Replimune will discuss fiscal second-quarter results on October 28, 2026. Replimune stock posted USD 0.72 loss per share versus USD 0.69 expected.

Results date and valuation context

Replimune announced its fiscal second-quarter update on October 22, 2026, for October 28, 2026.
Fiscal first-quarter earnings per share came to minus USD 0.72 versus a USD 0.69 consensus estimate on August 14, 2026.
Replimune had a USD 1.1 billion market capitalization and a USD 1.50 to USD 16.33 52-week range as of October 23, 2026.

REPL, US76029N1063, Illustration mit AI erstellt.

Replimune Group (ISIN US76029N1063) will discuss fiscal second-quarter 2027 results for the period ended September 30, 2026, on October 28, 2026. The company set the date in an announcement issued on October 22, 2026, according to Replimune.

October 28 brings the next test

The scheduled update will combine financial results with a corporate update and a conference call at 8:00 a.m. ET. The date gives investors a defined checkpoint for the commercial rollout of TUDRIQEV and the companys broader oncolytic immunotherapy pipeline.

Replimune is a commercial-stage biotechnology company developing cancer treatments based on its RPx platform, which uses an HSV-1 backbone designed to stimulate local tumor killing and a systemic immune response. The company trades on Nasdaq under the ticker REPL, according to Investing.com.

What does the next report mean?

The main benchmark is the fiscal first-quarter result. Replimune reported adjusted? No, the available earnings record identifies GAAP earnings per share of minus USD 0.72 for the quarter ended June 30, 2026, versus a consensus estimate of minus USD 0.69, a USD 0.03 shortfall, according to MarketBeat.

That comparison makes the October 28 release important for two reasons: it will show whether commercial activity is beginning to affect reported results and whether cash use remains the dominant financial theme. MarketBeat lists a consensus estimate of minus USD 0.78 earnings per share for fiscal second-quarter 2027 and USD 1.00 million of expected revenue.

Market value and business scale

Replimune had a USD 1.1 billion market capitalization as of October 23, 2026. Its 52-week range extended from USD 1.50 to USD 16.33, placing the company in a valuation story driven by clinical execution, regulatory progress and the adoption of its first commercial product.

Dates for the next update

The companys October 28, 2026, conference call is the next substantiated reporting date. The call is scheduled for 8:00 a.m. ET and covers the fiscal second quarter ended September 30, 2026.

Replimune enters its results window

The October 28 release will provide the next reported operating figures and management update for Replimune. The further course of trading is shown by the continuously updated real-time quote of Replimune stock.